Ossiam Lowers Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Ossiam trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 27.3% in the 4th quarter, Holdings Channel reports. The fund owned 9,504 shares of the medical equipment provider’s stock after selling 3,566 shares during the quarter. Ossiam’s holdings in Hologic were worth $685,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of HOLX. General Partner Inc. purchased a new position in shares of Hologic during the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Finally, Smithfield Trust Co raised its position in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 400 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Down 1.1 %

Hologic stock opened at $56.94 on Tuesday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $55.89 and a 12-month high of $84.67. The firm has a market capitalization of $12.78 billion, a price-to-earnings ratio of 17.96, a P/E/G ratio of 2.14 and a beta of 0.82. The firm has a 50 day moving average of $61.45 and a 200 day moving average of $70.54.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on HOLX shares. Royal Bank of Canada decreased their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Citigroup reduced their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Raymond James reaffirmed an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley lowered their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.